Slide 1: Preliminary Results Year Ended 30 June 2025
UU Genus Preliminary Results Year Ended 30 June 2025 Strong performance and substantial strategic progress achieved
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Genus plc (“Genus" or “the Company") and has not been independently verified. Genus is solely responsible for the contents of this document and has taken all reasonable care to ensure that the facts stated herein are true and accurate in all material
Slide 3: Overview & Headlines
Genus Overview & Headlines Jorgen Kokke Chief Executive Officer
Slide 4: CEO Overview
4 Overview & Headlines Financial Results Strategy & Outlook CEO Overview Strong performance, good strategic progress achieved fei we “= ® 2 - —s 4 wa Continued growth in porcine, Deliver successful commercialisation Drive greater value from bovine accelerated JV in China of our PRP gene edit and del
Slide 5: FY25 Headlines
5 Overview & Headlines Financial Results Strategy & Outlook FY25 Headlines Financial performance! Revenue Adj. operating profit including JVs? £6/2.8m £93.1m (+1%) (+19%) Adj. profit before tax? Full year dividend maintained £/4.5m $2.0p (+24%) per share Preliminary Results Year Ended 30 June 2025
Slide 6: H1 Market Outlook
Overview & Headlines H1 Market Outlook FY26 H1 Outlook: Generally stable Market Landscape Financial Results Strategy & Outlook Market Landscape FY25 REGIONAL HIGHLIGHTS FY26 H1 MARKET OUTLOOK' + Americas: Good margins for pork producers over the period + Europe: Continued disease challenges for cust
Slide 7: Sustainability
Sustainability Genus has a significant positive impact on industry sustainability Certified & quantifiable sustainability benefits + In FY25, PIC's European Life Cycle Assessment ("LCA") showed that conventional PIC genetics reduce emissions by greater than 7% compared to the industry average + PIC'
Slide 8: Financial Results
Genus miatelaterlel| Results Andy Russell Chief Financial Officer
Slide 9: Volume Growth
Overview & Headlines Financial Results Strategy & Outlook Volume Growth Strong volume growth in porcine, improved bovine volume trend and continued mix shift to sexed Genus PIC Genus ABS Volume growth (%) Volume growth (%) Total volume growth excluding China i Sexed volume growth Fy21 FY22 FY23 FY26
Slide 10: Genus Adjusted Profit Performance
10 Overview & Headlines Financial Results Strategy & Outlook Genus Adjusted Profit Performance Genus adjusted operating profit? £m FY25 FY24 %Change % Change Actual Currency (£m) actual actual actual constant! 89.8 93.1 Genus PIC m.g9 103.6 8% 16% Genus ABS 19.5 14.0 39% 53% a R&D (16.5) (21.8) 24%
Slide 11: Genus PIC
1 Genus PIC Adjusted operating profit! performance (£m) FY25 FY24 % actual actual Change Actual Constant £m £m Revenue 362.9 352.5 3% 8% Adjusted operating profit! m.g9 103.6 8% 16% Adjusted operating margin! 27.6% 26.6% 1.0pts 1.3pts 1. Adjusted operating profit includes joint ventures. Adjusted op
Slide 12: Genus PIC
12 Genus PIC Overview & Headlines Financial Results Strategy & Outlook Adjusted operating profit! Latin Royalty revenue ° America Royalty revenue growth 11%. +16% Volume growth 15% + +] 4 % Strong royalty growth in Mexico +8% in actual currency ° and Andina, coupled with higher +1% in actual JV reve
Slide 13: Genus ABS
3 Genus ABS Adjusted operating profit performance (Em) FY25 FY24 % actual actual Change £m £m Actual = Constant Currency Currency Revenue 307.7 3149 (2%) 2% Adjusted operating profit! 19.5 14.0 39% 53% Adjusted operating margin! 6.3% 44% 1.9pts 2.2pts Overview & Headlines Financial Results Strategy
Slide 14: Genus ABS
14 Genus ABS Overview & Headlines Financial Results Strategy & Outlook Cnt Latin Total volume growth was -2%, Sexed volume Beef volume sexed volume 7% and beef -6% America ictter dairy market conditions drove 0 ° _ 6 greater adoption of sexed genetics +7] % % + Beef cycle stabilised but demand for -
Slide 15: Genus Research and Product Development
15 Overview & Headlines Financial Results Strategy & Outlook Genus Research and Product Development Genus research and product development % of Genus revenue Genus continues to invest substantially in research and 1% 1% praciiet development a FY21 FY22 FY23 FY24 FY25 mmm R&D & PD Spending —=RE&D & P
Slide 16: Statutory Income
16 Overview & Headlines Financial Results Strategy & Outlook Statutory Income Statutory profit before tax £28.5M eeve4:¢s.5m) FY25 FY24 Change actual actual actual Non-cash impacts + £13.3m decrease in net IAS 41 biological assets Adjusted operating profit 811 67.0 141 primarily driven by bovine (FY
Slide 17: Free Cash Flow
7 Free Cash Flow Free cash flow! bridge Actual currency (£m) Free EBITDA — Higher Improved Lower Lower Increased Other(inc Free cashflow increase joint working biological ~~ capex exceptional tax, interest cash flow FY24 venture capital assets items leases) FY25 cash flows outfiow * Significantly im
Slide 18: Strong Financial Position
18 Overview & Headlines Strong Financial Position Significant decrease in leverage to 1.5x at June 2025 Net debt bridge Actual currency (£m) Free cash flow inc. lease repayments: £40.9m Financial Results 106.2 Net LJ Net Debt: (41.1) Debt: EBITDA’ EBITDA! 2.0x 15x (24.2) 83 — 21.1 — . (228.2) Gs) i
Slide 19: Capital Allocation
19 Overview & Headlines Capital Allocation Disciplined framework for capital allocation Organic @) growth opportunities Capital Allocation Framework balance sheet Preliminary Results Year Ended 30 June 2025 Financial Results Strategy & Outlook Shareholder returns Inorganic growth opportunities
Slide 20: Strategic Progress
Genus Strategic Progress Jorgen Kokke Chief Executive Officer
Slide 21: Genus's Strategic Priorities
21 Overview & Headlines Financial Results Strategy & Outlook Genus's Strategic Priorities ann = me 4, cae ™ ——s" 8 Continued growth in porcine, Deliver successful commercialisation Drive greater value from bovine accelerated JV in China of our PRP gene edit and deliver attractive returns from R&D EE
Slide 22: PIC Royalty Revenue
22 PIC Royalty Revenue Continued Growth Royalty revenue 4-year CAGR | Constant currency (£m) NAM 100 + Do 90 80 LATAM +11% EMEA 70 60 SO 40 30 20 10 ie} FY21 FY22 FY23 =™NAM =LATAM = EMEA FY24 FY25 Asia Royalty revenue underpins PIC's visibility and stability of growth in more developed markets High
Slide 23: PIC China
23 Overview & Headlines PIC China Commercial progress winning royalty customers Pig price to corn price ratio! PIC China royalty? vs non-royalty revenue (£m) 20 60 18 50 16 40 “4 50 20 12 10 10 7 8 Fy21 FY22 FY23 FY24 FY25 mRoyalty Revenue m Non-Royaiity Revenue 6 4 * Increase in PIC China profit dr
Slide 24: Global PRP Regulatory Progress
24 Overview & Headlines Financial Results Strategy & Outlook Global PRP Regulatory Progress Landmark U.S. FDA approval; continuing encouraging progress with other international regulators Sad Approved/favourable determination: * Argentina * Brazil (July 2025) (April 2024) + USA * Colombia (April 202
Slide 25: Driving Greater Value From Bovine
25 Overview & Headlines Financial Results Strategy & Outlook Driving Greater Value From Bovine Value acceleration programme Cunt Objectives unchanged: Return to growth and improve margin, ROIC and cash generation Accelerate value creation through . Objectives commercial excellence and Improve margin
Slide 26: ABS Value Acceleration Programme Progress
26 Overview & Headlines Financial Results Strategy & Outlook ABS Value Acceleration Programme Progress Phases 1 & 2 delivered; Phase 3 commenced Cunt VAP phase 1: VAP phase 2: VAP phase 3: 24 Achieved in FY25 in FY26 Expected in FY27 £3m ~£30m Cumulative Expected Peete pected Amused VAP Phase 1, £9
Slide 27: Accelerated porcine JV formation in China
Genus Accelerated porcine JV formation in China Jorgen Kokke Chief Executive Officer
Slide 28: Background
28 Background May 2019 - Announcement of strategic collaboration with BCA Genus \ i QB IRSREAARAG 'SUNLON BEIJING CAPITAL AGRIBUSINESS CO. LTD + Leading Chinese agribusiness with extensive poultry, dairy and porcine breeding interests * Owned by the Beijing Capital Agribusiness and Food Group (part
Slide 29: Updated agreements with BCA
Updated agreements with BCA Upfront value crystallisation and accelerated milestone receipt Terms of the original 2019 agreements Terms of the updated agreements Upfront cash consideration payment (expected US$140m, net of withholding tax, transaction costs, and any further working capital and net d
Slide 30: Key highlights of the new agreements
Key highlights of the new agreements Joint venture acceleration, in-line with our strategic priorities v) Localises our business and accelerates the long-term growth opportunity for PIC China Domestic partner collaboration with BCA, a leading state-backed agribusiness, provides the best possible rou
Slide 31: PRP progress in China
PRP progress in China China is the largest scalable market for our technology at Significant opportunity Ah Regulatory progress Joint venture acceleration Significant opportunity based on size of market and size of impact ~37m sows in the Chinese market ~6x larger than US Continued positive progress
Slide 32: Summary & Outlook
Genus Summary & Outlook Jorgen Kokke Chief Executive Officer
Slide 33: Summary & Outlook
33 Overview & Headlines Financial Results Strategy & Outlook Summary & Outlook Strong financial performance in FY25 and balance sheet deleveraged Outlook . Market conditions stable albeit caution PIC growing revenue, profit remains around potential geopolitical- and margins driven market volatility
Slide 34: Q&A
Q&A
Slide 35: Appendices
Appendices
Slide 36: Illustrative only, Genus Pro-Forma FY25 financials
Illustrative only, Genus Pro-Forma FY25 financials Assumes BCA transaction completion on 1 July 2024, and net proceeds entirely allocated to pay down debt £m Genus PIC Genus ex- 49% of Debt Genus FY25 | Accelerated | Genus FY25 (FY25) China PIC China | PIC China Repayment | Pro- Forma Milestone Pro-
Slide 37: Technical Guidance
37 Technical Guidance Area Adjusted Income Statement Items FY25 FY26 Expected Impacts Net Interest Effective Tax Rate Foreign Exchange ABS VAP Phase 2 benefit to adjusted operating profit ABS VAP Phase 3 benefit to adjusted operating profit Actual/Estimated Exceptional Items Cash Flow Statement Item
Slide 38: Financial Results
38 Financial Results Revenue Adjusted operating profit inc. JV Net finance costs Adjusted profit before tax Adjusted earnings per share (pence) Dividend per share (pence) Preliminary Results Year Ended 30 June 2025 93.1 (18.8) 743 81.8 32.0 78.1 (18.3) 59.8 65.5 32.0 % Change actual % Change constan
Slide 39: Free Cash Flow
39 Free Cash Flow FY25 performance Adjusted EBITDA Cash received from joint ventures Working capital Biological assets Net capital expenditure Lease repayments Adjusted cash generated by operations Cash conversion % Exceptional items Pension contributions, provisions & other Interest and tax paid Fr
Slide 40: Exchange Rate Sensitivity
40 Exchange Rate Sensitivity — FY25 Genus's geographic profile Average! can lead to translational currency impacts since als Euro 1.19 We monitor key rates Mexican Peso 25.8 against GBP US Dollar 1.29 Latest spot rates indicate a Brazilian Real TAT broadly neutral profit ° impact for FY26 compared w
Slide 41: Return on Invested Capital
4l Return on Invested Capital FY25 FY24 restated £m £m Adjusted operating profit inc JV 93.1 78.1 Tax rate 27.5% 28.1% Adjusted operating profit after tax 67.5 56.2 Equity attributable to owners of the company 4761 517.8 Add back: Net debt 228.2 248.7 Pension liability 69 6.6 Related deferred tax (1
Slide 42: Proportion of Total Porcine Volumes Under Royalty
42 Proportion of Total Porcine Volumes Under Royalty Sod North America EMEA ¢ 80% 80% 98% 97% 97% 97% 97% 79% 78% FY2I FY22 FY23 FY24 FY25 FY2I FY22 FY23 FY24 FY25 Latin America Asia! 84% se 67% aks 61% 78% 57% 70% aS FY21 FY22 FY23 FY24 FY25 : FY21 FY22 FY23 FY24 FY25 1. . PIC Chino's proportion of
Slide 43: Porcine Royalty Revenue Growth
43 Porcine Royalty Revenue Growth North America EMEA 8% 11% 7% 4% 7% ba -1% pl = FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 Latin America Asia! 70% 17% 2% 1% 20% 12% 6% -32% FY21 FY22 FY23 FY24 FY25 : FY21 FY22 FY23 FY24 FY2S Preliminary Results Year Ended 30 June 2025
Slide 44: Glossary
44 Glossary Artificial insemination (‘Al’) Using semen collected from a bull or boar to impregnate a cow or sow when in oestrus. Artificial insemination allows a genetically superior male to be used to mate with many more females than would be possible with natural mating. ASF African Swine Fever. B